{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:45:23Z","timestamp":1775709923139,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["neurotox res"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/bf03033930","type":"journal-article","created":{"date-parts":[[2009,7,20]],"date-time":"2009-07-20T17:58:17Z","timestamp":1248112697000},"page":"127-131","source":"Crossref","is-referenced-by-count":46,"title":["Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F"],"prefix":"10.1007","volume":"9","author":[{"given":"Roberto","family":"Eleopra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Tugnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Quatrale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"Rossetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,7]]},"reference":[{"key":"BF03033930_CR1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000060683","volume":"30","author":"KR Aoki","year":"2002","unstructured":"Aoki KR (2002) Physiology and pharmacology of therapeutic botulinum neurotoxins.Curr. Probl. Dermatol. 30, 107\u2013116.","journal-title":"Curr. Probl. Dermatol."},{"key":"BF03033930_CR2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/mus.10213","volume":"26","author":"CR Billante","year":"2002","unstructured":"Billante CR, DL Zealear, M Billante, JH Reyes, G Sant\u2019Anna, R Rodriguez and RE Stone Jr (2002) Comparison of neuromuscular blockade and recovery with botulinum toxins A and F.Muscle Nerve 26, 395\u2013403.","journal-title":"Muscle Nerve"},{"key":"BF03033930_CR3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.46.1.26","volume":"46","author":"G Borodic","year":"1996","unstructured":"Borodic G, E Johnson, M Goodnough and E Schantz (1996) Botulinum toxin therapy, immunologic resistance, and problem with available materials.Neurology 46, 26\u201329.","journal-title":"Neurology"},{"key":"BF03033930_CR4","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","volume":"53","author":"A Brashear","year":"1999","unstructured":"Brashear A, MF Lew, DD Dykstra, CL Comella, SA Factor, RL Rodnitzky, R Trosch, C Singer, MF Brin, JJ Murray, JD Wallace, A Willmer-Hulme and M koller (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.Neurology 53, 1439\u20131446.","journal-title":"Neurology"},{"key":"BF03033930_CR5","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1002\/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4","volume":"6","author":"M Brin","year":"1997","unstructured":"Brin M (1997) Botulinum toxin: chemistry, pharmacology, toxicity, and immunology.Muscle Nerve (Suppl.)6, S146-Sl65.","journal-title":"Muscle Nerve (Suppl.)"},{"key":"BF03033930_CR6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","volume":"53","author":"MF Brin","year":"1999","unstructured":"Brin MF, MF Lew, CH Adler, CL Comella, SA Factor, J Jankovic, C o\u2019Brien, JJ Murray, JD Wallace, A Willmer-Hulme and M Koller (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.Neurology 53, 1431\u20131438.","journal-title":"Neurology"},{"key":"BF03033930_CR7","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1212\/WNL.51.5.1494","volume":"51","author":"R Chen","year":"1998","unstructured":"Chen R, BI Karp and M Hallett (1998) Botulinum toxin type F for treatment of dystonia: long-term experience. Botulinum toxin type F for treatment of dystonia: long-term experience.Neurology 51, 1494\u20131496.","journal-title":"Neurology"},{"key":"BF03033930_CR8","first-page":"211","volume-title":"Therapy with Botulinum Toxin","author":"ES Consky","year":"1994","unstructured":"Consky ES and AE Lang (1994) Clinical assessments of patients with cervical dystonia, In:Therapy with Botulinum Toxin (Jankovic J and M Hallett, Eds.) (Marcel Dekker:New York), pp 211\u2013237."},{"key":"BF03033930_CR9","volume-title":"Botulinum Toxin Therapy","author":"D Dressler","year":"2000","unstructured":"Dressler D (2000)Botulinum Toxin Therapy (Thieme Verlag: Stuttgart, New York)."},{"issue":"19 Suppl","key":"BF03033930_CR10","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","volume":"8","author":"D Dressler","year":"2004","unstructured":"Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.Mov. Disord. 19 Suppl8, S92-S100. Review.","journal-title":"Mov. Disord."},{"key":"BF03033930_CR11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000067023","volume":"49","author":"D Dressler","year":"2003","unstructured":"Dressler D and R Benecke (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.Eur. Neurol. 49, 34\u201338.","journal-title":"Eur. Neurol."},{"key":"BF03033930_CR12","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00415-003-1129-6","volume":"250","author":"D Dressler","year":"2003","unstructured":"Dressler D, R Benecke and H Bigalke (2003a) Botulinum toxin type B (NeuroBloc\u00ae) in patients with botulinum toxin type A antibody-induced therapy failure.J. Neurol. 250, 967\u2013969.","journal-title":"J. Neurol."},{"issue":"Suppl. 1","key":"BF03033930_CR13","first-page":"465","volume":"60","author":"D Dressler","year":"2003","unstructured":"Dressler D, H Bigalke and R Benecke (2003b) Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.Neurology 60 (Suppl. 1), 465\u2013466.","journal-title":"Neurology"},{"issue":"Suppl. 2","key":"BF03033930_CR14","first-page":"51","volume":"15","author":"D Dressler","year":"2000","unstructured":"Dressler D and G Dirnberger (2000) Botulinum toxin therapy: risk factors for therapy failure.Mov. Disord. 15 (Suppl. 2), 51.","journal-title":"Mov. Disord."},{"key":"BF03033930_CR15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3940(97)13448-6","volume":"224","author":"R Eleopra","year":"1997","unstructured":"Eleopra R, V Tugnoli, o Rossetto, C Montecucco and D De Grandis (1997) Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in humans.Neurosci. Lett. 224, 91\u201394.","journal-title":"Neurosci. Lett."},{"issue":"Suppl. 4","key":"BF03033930_CR16","first-page":"72","volume":"50","author":"R Eleopra","year":"1998","unstructured":"Eleopra R, V Tugnoli, D De Grandiset al. (1998) Botulinum toxin serotype C treatment in subjects affected by focal dystonia and resistant to botulinum toxin serotype A.Neurology 50, (Suppl. 4), 72.","journal-title":"Neurology"},{"key":"BF03033930_CR17","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S1388-2457(02)00103-7","volume":"113","author":"R Eleopra","year":"2002","unstructured":"Eleopra R, V Tugnoli, R Quatrale, E Gastaldo, o Rossetto, D De Grandis and C Montecucco (2002) Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.Clin. Neurophysiol. 113, 1258\u20131264.","journal-title":"Clin. Neurophysiol."},{"issue":"Suppl. 8","key":"BF03033930_CR18","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1002\/mds.20010","volume":"19","author":"R Eleopra","year":"2004","unstructured":"Eleopra R, V Tugnoli, R Quatrale, O Rossetto and C Montecucco (2004) Different types of botulinum toxin in humans.Mov. Disord. 19 (Suppl. 8), S53-S59.","journal-title":"Mov. Disord."},{"key":"BF03033930_CR19","first-page":"285","volume":"84","author":"JS Elston","year":"1990","unstructured":"Elston JS (1990) Botulinum toxin A in clinical medicine.J. Physiol. (Paris) 84, 285\u2013289.","journal-title":"J. Physiol. (Paris)"},{"key":"BF03033930_CR20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.870080411","volume":"8","author":"PE Greene","year":"1993","unstructured":"Greene PE and S Fahn (1993) Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.Mov. Disord. 8, 479\u2013483.","journal-title":"Mov. Disord."},{"key":"BF03033930_CR21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/mds.870110211","volume":"11","author":"PE Greene","year":"1996","unstructured":"Greene PE and S Fahn (1996) Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients.Mov. Disord. 11, 181\u2013184.","journal-title":"Mov. Disord."},{"key":"BF03033930_CR22","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/mus.880171207","volume":"17","author":"JA Hamjian","year":"1994","unstructured":"Hamjian JA and Fo Walker (1994) Serial neurophysiological studies of intramuscular botulinum A toxin in humans.Muscle Nerve 17, 1385\u20131392.","journal-title":"Muscle Nerve"},{"key":"BF03033930_CR23","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/WNL.50.6.1624","volume":"50","author":"PA Hanna","year":"1998","unstructured":"Hanna PA and J Jankovic (1998) Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response.Neurology 50, 1624\u20131629.","journal-title":"Neurology"},{"issue":"5","key":"BF03033930_CR24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jnnp.64.5.577","volume":"64","author":"MK Houser","year":"1998","unstructured":"Houser MK, GL Sheean and AJ Lees (1998) Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A.J. Neurol. Neurosurg. Psychiatry 64(5), 577\u2013580.","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BF03033930_CR25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0300-9084(00)00216-9","volume":"82","author":"Y Humeau","year":"2000","unstructured":"Humeau Y, F Doussau, NJ Grant and B Poulain (2000) How botulinum and tetanus neurotoxins block neurotransmitter release.Biochimie 82, 427\u2013446.","journal-title":"Biochimie"},{"key":"BF03033930_CR26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","volume":"75","author":"J Jankovic","year":"2004","unstructured":"Jankovic J (2004) Botulinum toxin in clinical practice.J. Neurol. Neurosurg. Psychiatry 75, 951\u2013957.","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BF03033930_CR27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","volume":"49","author":"MF Lew","year":"1997","unstructured":"Lew MF, BT Adornato, DD Duane, DD Dykstra, SA Factor, JM Massey, MF Brin, J Jankovic, RL Rodnitzky, C Singer, MR Swenson, D Tarsy, JJ Murray, M koller and JD Wallace (1997) Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.Neurology 49, 701\u2013707.","journal-title":"Neurology"},{"key":"BF03033930_CR28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJM199201303260516","volume":"326","author":"CL Ludlow","year":"1992","unstructured":"Ludlow CL, M Hallett, K Rhew, R Cola, T Shin\u00ecizu, G Sakaguchi, JA Bagley, GM Schulz, SG Yin and J Koda (1992) Therapeutic use of type F botulinum toxin.New Engl. J. Med. 326, 349\u2013350.","journal-title":"New Engl. J. Med."},{"key":"BF03033930_CR29","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1212\/WNL.45.3.506","volume":"45","author":"T Mezaki","year":"1995","unstructured":"Mezaki T, R kaji, N kohara, H Fujii, M katayama, T Shimizu, J Kimura and MF Brin (1995) Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study.Neurology 45, 506\u2013508.","journal-title":"Neurology"},{"key":"BF03033930_CR30","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/1531-8257(199911)14:6<1017::AID-MDS1018>3.0.CO;2-3","volume":"14","author":"T Mezaki","year":"1999","unstructured":"Mezaki T, R kaji, MF Brin, M Hirota-katayama, T kubori, T Shimizu and J Kimura (1999) Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial.Mov. Disord. 14, 1017\u20131020","journal-title":"Mov. Disord."},{"key":"BF03033930_CR31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1017\/S0033583500003292","volume":"28","author":"C Montecucco","year":"1994","unstructured":"Montecucco C and G Schiavo (1994) Mechanism of action of tetanus and botulinum neurotoxins.Quart. Rev. Biophys. 28, 423\u2013472.","journal-title":"Quart. Rev. Biophys."},{"key":"BF03033930_CR32","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/0140-6736(90)93157-K","volume":"336","author":"K Oguma","year":"1990","unstructured":"Oguma K, K Yokota, S Hayashi, M Takeshi, M kumagai, N Itoh, N Tachi and S Chiba (1990) Infant botulism due toClostridium botulinum type C toxin.Lancet 336, 1449\u20131450.","journal-title":"Lancet"},{"key":"BF03033930_CR33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/mds.870130128","volume":"13","author":"C Sankhla","year":"1998","unstructured":"Sankhla C, J Jankovic and D Duane (1998) Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.Mov. Disord. 13, 150\u2013154.","journal-title":"Mov. Disord."},{"key":"BF03033930_CR34","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","volume":"80","author":"Schiavo G","year":"2000","unstructured":"Schiavo G, M Matteoli and C Montecucco (2000) Neurotoxins affecting neuroexocytosis.Physiol. Rev. 80, 717\u2013766.","journal-title":"Physiol. Rev."},{"issue":"6","key":"BF03033930_CR35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/jnnp.59.6.601","volume":"59","author":"GL Sheean","year":"1995","unstructured":"Sheean GL and AJ Lees (1995) Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.J. Neurol. Neurosurg. Psychiatry 59(6), 601\u2013607.","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BF03033930_CR36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.49.1.189","volume":"49","author":"RR Sloop","year":"1997","unstructured":"Sloop RR, BA Cole and Ro Escutin (1997) Human response to botulinum toxin injection: type B compared with type A.Neurology 49, 189\u2013194.","journal-title":"Neurology"},{"key":"BF03033930_CR37","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1212\/WNL.45.11.2109","volume":"45","author":"JKC Tsui","year":"1995","unstructured":"Tsui JKC, M Hayward, EK Ming Mak and M Schulzer (1995) Botulinum toxin type B in the treatment of cervical dystonia: a pilot study.Neurology 45, 2109\u20132110.","journal-title":"Neurology"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03033930.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03033930\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03033930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:44:53Z","timestamp":1558572293000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03033930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":37,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["BF03033930"],"URL":"https:\/\/doi.org\/10.1007\/bf03033930","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}